A Phase 1 interventional study of BMS-986365 and Itraconazole in Healthy Volunteers, sponsored by Celgene. Terminated at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted after Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986365 · Drug: Itraconazole
Drug: BMS-986365
Drug: BMS-986365 · Drug: Itraconazole
Drug: BMS-986365
Drug: BMS-986365 · Drug: Rifampin
Specified dose on specified days
Also known as: AR-LDD, CC-94676
Specified dose on specified days
Also known as: SPORANOX®
Specified dose on specified days
Part A: Maximum Observed Plasma Concentration (Cmax) of BMS-986365
Time frame: Up to approximately Day 32
Part A: Cmax of BMS-986365 Without Itraconazole
Time frame: Up to approximately Day 32
Part A: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986365 With Itraconazole
Time frame: Up to approximately Day 32
Part A: AUC(0-T) of BMS-986365 Without Itraconazole
Time frame: Up to approximately Day 32
Part A: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986365
Time frame: Up to approximately Day 32
Part A: AUC(INF) of BMS-986365 Without Itraconazole
Time frame: Up to approximately Day 32
Part B: Cmax of BMS-986365 With Rifampin
Time frame: Up to approximately Day 37
Part B: Cmax of BMS-986365 Without Rifampin
Time frame: Up to approximately Day 37
Part B: AUC(INF) of BMS-986365 With Rifampin
Time frame: Up to approximately Day 37
Part B: AUC(INF) of BMS-986365 Without Rifampin
Time frame: Up to approximately Day 37
Part B: AUC(0-T) of BMS-986365 With Rifampin
Time frame: Up to approximately Day 37
Part B: AUC(0-T) of BMS-986365 Without Rifampin
Time frame: Up to approximately Day 37
Number of Participants With Adverse Events (AEs)
Time frame: Up to approximately Day 89
Number of Participants With Serious Adverse Events (SAEs)
Time frame: Up to approximately Day 89
Number of Participants With AEs Leading to Drug/Study Discontinuation
Time frame: Up to approximately Day 89
Number of Participants With Clinically Significant Vital Sign Measurements
Time frame: Up to approximately Day 77
Number of Participants With Clinically Significant Laboratory Safety Tests
Laboratory safety tests include hematology, chemistry, and urinalysis.
Time frame: Up to approximately Day 77
Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Abnormalities
Time frame: Up to approximately Day 77
Number of Participants With Clinically Significant Physical Examination (PE) Abnormalities
Time frame: Up to approximately Day 77
Change From Baseline of Corrected QT Interval (QTc) Post Dose of BMS-986365
Time frame: Up to approximately Day 77
Part A: Change From Baseline of QTc Post Dose of BMS-986365 With Itaconazole
Time frame: Up to approximately Day 72
Part B: Change From Baseline of QTc Post Dose of BMS-986365 With Rifampin
Time frame: Up to approximately Day 77
Time of Maximum Observed Plasma Concentration (Tmax) of BMS-986365
Time frame: Up to approximately Day 77
Apparent Terminal Plasma Half-life (T-HALF) of BMS-986365
Time frame: Up to approximately Day 77
Apparent Total Body Clearance (CLT/F) of BMS-986365
Time frame: Up to approximately Day 77
Apparent Volume of Distribution of Terminal Phase (Vz/F) of BMS-986365
Time frame: Up to approximately Day 77
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Dec 2025 to primary completion in Apr 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dezandrodeg